Latest Distributions News

Sandon Capital Investments Limited has announced a fully franked ordinary dividend of AUD 0.014 per share for the quarter ending December 2024, payable in March 2025. The company’s Dividend Reinvestment Plan remains active, offering shareholders flexibility in participation.

Sigma Healthcare has received Federal Court approval for its acquisition of Chemist Warehouse, marking a pivotal step in its strategic expansion. The scheme is set to become legally effective on February 4, 2025, with implementation expected by February 12.

ARGO Investments Limited has announced a fully franked ordinary dividend of AUD 0.17 per share for the six months ending December 31, 2024, with payment scheduled for March 14, 2025. Shareholders can opt into a Dividend Reinvestment Plan or Bonus Security Plan, both without discounts.

Plato Income Maximiser Limited has announced a fully franked ordinary dividend of AUD 0.0055 per share, payable on February 28, 2025, signaling steady income returns for shareholders.

Nova Minerals' 2024 exploration at the RPM Regional area reveals high-grade gold samples, including a standout 52.3 g/t Au, highlighting significant resource potential at the Estelle Project in Alaska.

Hearts and Minds Investments Limited has announced a fully franked ordinary dividend of AUD 0.08 per share, payable on April 17, 2025, with an active Dividend Reinvestment Plan available to shareholders.

Argo Investments reported a 3.2% decline in half-year profit to $121.2 million but announced a higher fully franked interim dividend of 17.0 cents per share, reflecting confidence in its long-term strategy.

Hearts and Minds Investments (HM1) has reported a robust 23.6% increase in its investment portfolio over six months, prompting an early announcement of an increased fully franked half-year dividend of 8.0 cents per share.

Podium Minerals has become the first Australian platinum group metals developer to join the World Platinum Investment Council, gaining access to vital market intelligence and global industry engagement ahead of production.

Yowie Group’s Q2 FY25 results reveal a mixed performance with a 33% revenue drop in North America offset by growth in Australia and ongoing cost optimisation efforts.

Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.

Skin Elements Limited reports steady progress in commercialising its plant-based SE Formula biotechnology, highlighted by ongoing product trials, a successful R&D rebate, and a $513k non-renounceable entitlement issue.